MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers

Cancer Biology and Therapy

Volumn 13, Issue 3, 2012, Pages 175-183

  Chandramouli, Anupama ^a   Onyeagucha, Benjamin Chidi ^a   Mercado Pimentel, Melania E ^a   Stankova, Lenka ^a   Abu Shahin, Nisreen ^a   LaFleur, Bonnie J ^a   Heimark, Ronald L ^a   Bhattacharyya, Achyut K ^a   Nelson, Mark A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Colorectal cancer; EP4; miR 101; Post transcriptional regulation

Indexed keywords

MICRORNA; MICRORNA 101; PROSTAGLANDIN E RECEPTOR 4; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84857072181     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.3.18874     Document Type: Article

References (43)

1. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69; PMID:12775730; http://dx. doi.org/10.1200/JCO.2003. 11.126
2. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12:900-9; PMID:16184442; http://dx.doi.org/10.1245/ASO. 2005.01.010
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87; PMID: 15689586; http://dx.doi.org/10.1056/NEJMra040958
4. Rougier P, Van Cutsem E, Bajetta E, Niderele N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12; PMID: 9807986; http://dx.doi.org/10.1016/S0140- 6736(98) 03085-2
5. Rougier P, Paillot B, LaPlanche A, Morvan F, Seitz JF, Rekacewicz C, et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 1997; 33:1789-93; PMID:9470834; http://dx.doi.org/10.1016/ S0959- 8049(97)00175-5
6. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23:2840-55; PMID:15837998; http://dx.doi.org/10. 1200/JCO.2005.09.051
7. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007; 58:239-52; PMID:17100552; http://dx.doi.org/10. 1146/annurev.med.57.121304.131253
8. Chell S, Kaidi A, Williams AC, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/ treatment of colorectal cancer. Biochim Biophys Acta 2006; 1766:104-19; PMID:16859832
9. Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, et al. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 2007; 313:2969-79; PMID: 17631291; http://dx.doi.org/10.1016/j.yexcr.2007.06. 004
10. Hawcroft G, Ko CW, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26:3006-19; PMID:17130837; http://dx.doi. org/10.1038/sj.onc.1210113
11. Chell SD, Witherden IR, Dobson RR, Moorghen M, Hermann AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006; 66:3106-13; PMID:16540660; http://dx.doi.org/10.1158/0008-5472.CAN-05-3702
12. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10:181-93; PMID:20168319; http://dx. doi.org/10.1038/nrc2809
13. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923- 7; PMID:16540639; http://dx.doi.org/10.1158/0008-5472.CAN-05-4348
14. Cha YI, Kim SH, Sepich D, Buchanan FG, Solnica- Krezel L, DuBois RN. Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. Genes Dev 2006; 20:77-86; PMID:16391234; http://dx.doi.org/ 10.1101/gad.1374506
15. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-81; PMID:11278548; http://dx.doi.org/10. 1074/jbc.M009689200
16. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, et al. PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras- PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 2007; 293:G673-81; PMID:17640974; http://dx.doi. org/10.1152/ajpgi.00584.2006
17. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002; 62:28-32; PMID: 11782353
18. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66:9665- 72; PMID:17018624; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-1271
19. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 2004; 279:29797- 804; PMID:15123663; http://dx.doi.org/10.1074/jbc. M313989200
20. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID: 17060945; http://dx.doi.org/10.1038/nrc1997
21. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101:11755- 60; PMID:15284443; http://dx.doi.org/10.1073/pnas. 0404432101
22. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18:504-11; PMID:15014042; http://dx.doi.org/10. 1101/gad.1184404
23. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107:6982-7; PMID:20351277; http://dx.doi. org/10.1073/pnas. 1002472107
24. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK. MicroRNA regulation of cyclo-oxygenase- 2 during embryo implantation. Proc Natl Acad Sci USA 2007; 104:15144-9; PMID:17848513; http://dx.doi.org/10.1073/pnas. 0705917104
25. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010; 101:241-9; PMID:19891660; http://dx.doi. org/10.1111/j.1349-7006.2009.01385.x
26. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69:1135-42; PMID:19155302; http://dx.doi.org/ 10.1158/0008-5472.CAN-08-2886
27. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322:1695-9; PMID:19008416; http://dx.doi.org/10.1126/ science.1165395
28. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315:1439-47; PMID: 19133256; http://dx.doi.org/10.1016/j.yexcr.2008.12. 010
29. Chandramouli A, Mercado-Pimentel ME, Hutchinson A, Gibadulinova A, Olson ER, Dickinson S, et al. The induction of S100p expression by the Prostaglandin E (PGE)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol Ther 2010; 10:1056-66; PMID: 20890108; http://dx.doi.org/10.4161/cbt.10.10.13373
30. Alvarez-Díaz S, Valle N, Garcia JM, Pena C, Freije JM, Quesada V, et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest 2009; 119:2343-58; PMID: 19662683; http://dx.doi.org/10.1172/JCI37205
31. Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham JT, Nelosn MA, et al. Loss of the eukaryotic initiation factor 3f in pancreatic cancer. Mol Carcinog 2008; 47:235-44; PMID:17918192; http:// dx.doi.org/10.1002/mc.20379
32. Deryugina EI, Quigley JP. Chapter 2. Chick embryo chorioallantoic membrane models to quantify angio-genesis induced by inflammatory and tumor cells or purified effector molecules. Methods Enzymol 2008; 444:21-41; PMID:19007659; http://dx.doi.org/10. 1016/S0076-6879(08)02802-4
33. Deryugina EI, Quigley JP. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 2008; 130:1119-30; PMID:19005674; http://dx.doi. org/10.1007/s00418-008-0536-2
34. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 2007; 121:232-40; PMID:17290397; http:// dx.doi.org/10.1002/ijc.22582
35. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003; 2:179-91; PMID:12612644; http://dx.doi.org/10.1038/nrd1034
36. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos- Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-8; PMID:11087881; http://dx.doi.org/10.1056/NEJM200011233432103
37. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R. Finn, Pet al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80; PMID:15713944; http://dx.doi.org/10. 1056/NEJMoa050405
38. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9; PMID:18030055; http://dx.doi.org/10.1097/ FJC.0b013e318157f72d
39. Gauvreau D, Dolman SJ, Hughes G, O'Shea PD, Davies IW. Scalable synthesis of a prostaglandin EP4 receptor antagonist. J Org Chem 2010; 75:4078-85; PMID:20469914; http://dx.doi.org/10.1021/jo1004197
40. Burch JD, Farand J, Colucci J, Sturino C, Ducharme Y, Friesen RW, et al. Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor. Bioorg Med Chem Lett 2011; 21:1041- 6; PMID:21215624; http://dx.doi.org/10.1016/j.bmcl. 2010.12.014
41. Li L, Mathieu MC, Denis D, Therien AG, Wang Z. The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid. Bioorg Med Chem Lett 2011; 21:734-7; PMID:21208803; http://dx.doi.org/10. 1016/j.bmcl.2010.11.118
42. Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, et al. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol 2010; 160:292-310; PMID:20423341; http://dx.doi.org/10.1111/j.1476- 5381.2010.00647.x
43. Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, Cloos J, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011; 6:e16282; PMID:21297974; http://dx. doi.org/10.1371/journal.pone.0016282